{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T01:59:33Z","timestamp":1792202373139,"version":"4.4.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2017,1,9]],"date-time":"2017-01-09T00:00:00Z","timestamp":1483920000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s13318-016-0399-1","type":"journal-article","created":{"date-parts":[[2017,1,9]],"date-time":"2017-01-09T07:53:59Z","timestamp":1483948439000},"page":"745-756","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["A Review of Pharmacogenetics of Antimalarials and Associated Clinical Implications"],"prefix":"10.1007","volume":"42","author":[{"given":"Hazem","family":"Elewa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle John","family":"Wilby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,1,9]]},"reference":[{"key":"399_CR1","unstructured":"WHO. WHO malaria fact sheet. 2016. http:\/\/www.who.int\/mediacentre\/factsheets\/fs094\/en\/ . Accessed 20 Oct 2016."},{"issue":"9918","key":"399_CR2","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/s0140-6736(13)60024-0","volume":"383","author":"NJ White","year":"2014","unstructured":"White NJ, Pukrittayakamee S, Hien TT, Faiz MA, Mokuolu OA, Dondorp AM. Malaria. Lancet. 2014;383(9918):723\u201335. doi: 10.1016\/s0140-6736(13)60024-0 .","journal-title":"Lancet."},{"key":"399_CR3","unstructured":"WHO. Guidelines for the treatment of malaria. 3rd edn. 2016. http:\/\/apps.who.int\/iris\/bitstream\/10665\/162441\/1\/9789241549127_eng.pdf . Accessed 20 Oct 2016."},{"issue":"11","key":"399_CR4","doi-asserted-by":"crossref","first-page":"705","DOI":"10.2165\/11594550-000000000-00000","volume":"50","author":"KJ Wilby","year":"2011","unstructured":"Wilby KJ, Ensom MH. Pharmacokinetics of antimalarials in pregnancy. Clin Pharmacokinet. 2011;50(11):705\u201323.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"399_CR5","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s40262-013-0110-5","volume":"53","author":"TK Kiang","year":"2014","unstructured":"Kiang TK, Wilby KJ, Ensom MH. Clinical pharmacokinetic drug interactions associated with artemisinin derivatives and HIV-antivirals. Clin Pharmacokinet. 2014;53(2):141\u201353.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"399_CR6","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1056\/NEJMp1403340","volume":"371","author":"RM Packard","year":"2014","unstructured":"Packard RM. The origins of antimalarial-drug resistance. N Engl J Med. 2014;371(5):397\u20139.","journal-title":"N Engl J Med"},{"issue":"6","key":"399_CR7","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1128\/AAC.48.6.2116-2123.2004","volume":"48","author":"ML Gatton","year":"2004","unstructured":"Gatton ML, Martin LB, Cheng Q. Evolution of resistance to sulfadoxine\u2013pyrimethamine in Plasmodium falciparum. Antimicrob Agents Chemother. 2004;48(6):2116\u201323.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9432","key":"399_CR8","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0140-6736(04)16767-6","volume":"364","author":"RN Price","year":"2004","unstructured":"Price RN, Uhlemann A-C, Brockman A, McGready R, Ashley E, Phaipun L, et al. Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet. 2004;364(9432):438\u201347.","journal-title":"Lancet"},{"issue":"5","key":"399_CR9","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1314981","volume":"371","author":"EA Ashley","year":"2014","unstructured":"Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2014;371(5):411\u201323.","journal-title":"N Engl J Med"},{"issue":"1","key":"399_CR10","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/1475-2875-7-229","volume":"7","author":"W Pongtavornpinyo","year":"2008","unstructured":"Pongtavornpinyo W, Yeung S, Hastings IM, Dondorp AM, Day NP, White NJ. Spread of anti-malarial drug resistance: mathematical model with implications for ACT drug policies. Malaria J. 2008;7(1):229.","journal-title":"Malaria J."},{"issue":"2","key":"399_CR11","doi-asserted-by":"crossref","first-page":"231","DOI":"10.4269\/ajtmh.2012.12-0025","volume":"87","author":"RM Fairhurst","year":"2012","unstructured":"Fairhurst RM, Nayyar GM, Breman JG, Hallett R, Vennerstrom JL, Duong S, et al. Artemisinin-resistant malaria: research challenges, opportunities, and public health implications. Am J Trop Med Hyg. 2012;87(2):231\u201341.","journal-title":"Am J Trop Med Hyg"},{"issue":"4 Pt 2","key":"399_CR12","first-page":"591","volume":"29","author":"MM Shi","year":"2001","unstructured":"Shi MM, Bleavins MR, de la Iglesia FA. Pharmacogenetic application in drug development and clinical trials. Drug Metab Dispos. 2001;29(4 Pt 2):591\u20135.","journal-title":"Drug Metab Dispos"},{"issue":"21","key":"399_CR13","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMra0907175","volume":"362","author":"WG Feero","year":"2010","unstructured":"Feero WG, Guttmacher AE, Collins FS. Genomic medicine\u2014an updated primer. N Engl J Med. 2010;362(21):2001\u201311. doi: 10.1056\/NEJMra0907175 .","journal-title":"N Engl J Med"},{"issue":"6","key":"399_CR14","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s00216-008-2291-6","volume":"392","author":"UM Zanger","year":"2008","unstructured":"Zanger UM, Turpeinen M, Klein K, Schwab M. Functional pharmacogenetics\/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem. 2008;392(6):1093\u2013108.","journal-title":"Anal Bioanal Chem"},{"issue":"9","key":"399_CR15","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.2217\/pgs.09.82","volume":"10","author":"EB Daily","year":"2009","unstructured":"Daily EB, Aquilante CL. Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies. Pharmacogenomics. 2009;10(9):1489\u2013510. doi: 10.2217\/pgs.09.82 .","journal-title":"Pharmacogenomics."},{"issue":"12","key":"399_CR16","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/s1473-3099(09)70320-2","volume":"9","author":"R Kerb","year":"2009","unstructured":"Kerb R, Fux R, Morike K, Kremsner PG, Gil JP, Gleiter CH, et al. Pharmacogenetics of antimalarial drugs: effect on metabolism and transport. Lancet Inf Dis. 2009;9(12):760\u201374. doi: 10.1016\/s1473-3099(09)70320-2 .","journal-title":"Lancet Inf Dis."},{"issue":"7","key":"399_CR17","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1097\/00008571-200110000-00006","volume":"11","author":"D Dai","year":"2001","unstructured":"Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI, et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenet Genomics. 2001;11(7):597\u2013607.","journal-title":"Pharmacogenet Genomics"},{"issue":"2","key":"399_CR18","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1124\/jpet.300.2.399","volume":"300","author":"X-Q Li","year":"2002","unstructured":"Li X-Q, Bj\u00f6rkman A, Andersson TB, Ridderstr\u00f6m M, Masimirembwa CM. Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate. J Pharm Exp Ther. 2002;300(2):399\u2013407.","journal-title":"J Pharm Exp Ther."},{"issue":"1","key":"399_CR19","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0024-3205(85)90285-1","volume":"36","author":"FC Churchill","year":"1985","unstructured":"Churchill FC, Patchen LC, Campbell CC, Schwartz IK, Nguyen-Dinh P, Dickinson CM. Amodiaquine as a prodrug: importance of metabolite (s) in the antimalarial effect of amodiaquine in humans. Life Sci. 1985;36(1):53\u201362.","journal-title":"Life Sci"},{"issue":"2","key":"399_CR20","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/sj.clpt.6100122","volume":"82","author":"S Parikh","year":"2007","unstructured":"Parikh S, Ouedraogo JB, Goldstein J, Rosenthal P, Kroetz D. Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa. Clin Pharm Ther. 2007;82(2):197\u2013203.","journal-title":"Clin Pharm Ther."},{"issue":"12","key":"399_CR21","doi-asserted-by":"crossref","first-page":"4400","DOI":"10.1128\/AAC.00673-07","volume":"52","author":"GO Adjei","year":"2008","unstructured":"Adjei GO, Kristensen K, Goka BQ, Hoegberg LC, Alifrangis M, Rodrigues OP, et al. Effect of concomitant artesunate administration and cytochrome P4502C8 polymorphisms on the pharmacokinetics of amodiaquine in Ghanaian children with uncomplicated malaria. Antimicrob Agents Chemother. 2008;52(12):4400\u20136.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"399_CR22","doi-asserted-by":"publisher","first-page":"184","DOI":"10.3109\/15376516.2011.623331","volume":"22","author":"W Yusof","year":"2012","unstructured":"Yusof W, Hua GS. Gene, ethnic and gender influences predisposition of adverse drug reactions to artesunate among Malaysians. Toxicol Mech Methods. 2012;22(3):184\u201392. doi: 10.3109\/15376516.2011.623331 .","journal-title":"Toxicol Mech Methods."},{"issue":"17","key":"399_CR23","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.2217\/pgs-2016-0131","volume":"17","author":"VA Sortica","year":"2016","unstructured":"Sortica VA, Lindenau JD, Cunha MG, Ohnishi MD, Ventura AMR, Ribeiro-dos-Santos \u00c2K et al. The effect of SNPs in CYP450 in chloroquine\/primaquine Plasmodium vivax malaria treatment. Pharmacogenomics. 2016;17(17):1903\u201311.","journal-title":"Pharmacogenomics."},{"issue":"6","key":"399_CR24","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1124\/dmd.31.6.748","volume":"31","author":"D Projean","year":"2003","unstructured":"Projean D, Baune B, Farinotti R, Flinois J-P, Beaune P, Taburet A-M, et al. In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation. Drug Metab Disp. 2003;31(6):748\u201354.","journal-title":"Drug Metab Disp."},{"issue":"6","key":"399_CR25","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/j.1365-2125.1991.tb05594.x","volume":"31","author":"S Ward","year":"1991","unstructured":"Ward S, Helsby N, Skjelbo E, Brosen K, Gram L, Breckenridge A. The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism-a panel study. Br J Clin Pharm. 1991;31(6):689\u201392.","journal-title":"Br J Clin Pharm."},{"issue":"3","key":"399_CR26","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1080\/00034983.1984.11811816","volume":"78","author":"W Watkins","year":"1984","unstructured":"Watkins W, Sixsmith D, Chulay J. The activity of proguanil and its metabolites, cycloguanil and p-chlorophenylbiguanide, against Plasmodium falciparum in vitro. Ann Trop Med Parasitol. 1984;78(3):273\u20138.","journal-title":"Ann Trop Med Parasitol"},{"issue":"3","key":"399_CR27","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/BF00271366","volume":"44","author":"J Wangboonskul","year":"1993","unstructured":"Wangboonskul J, White N, Nosten F, Ter Kuile F, Moody R, Taylor R. Single dose pharmacokinetics of proguanil and its metabolites in pregnancy. Eur J Clin Pharmacol. 1993;44(3):247\u201351.","journal-title":"Eur J Clin Pharmacol"},{"issue":"9","key":"399_CR28","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.2217\/pgs.09.72","volume":"10","author":"RE Janha","year":"2009","unstructured":"Janha RE, Sisay-Joof F, Hamid-Adiamoh M, Worwui A, Chapman HL, Opara H, et al. Effects of genetic variation at the CYP2C19\/CYP2C9 locus on pharmacokinetics of chlorcycloguanil in adult Gambians. Pharmacogenomics. 2009;10(9):1423\u201331.","journal-title":"Pharmacogenomics."},{"issue":"4","key":"399_CR29","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.tips.2004.02.007","volume":"25","author":"M Ingelman-Sundberg","year":"2004","unstructured":"Ingelman-Sundberg M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol Sci. 2004;25(4):193\u2013200. doi: 10.1016\/j.tips.2004.02.007 .","journal-title":"Trends Pharmacol Sci"},{"key":"399_CR30","doi-asserted-by":"publisher","unstructured":"Elewa H, El-Mekaty E, El-Bardissy A, Ensom MH, Wilby K. Therapeutic drug monitoring of voriconazole in the management of invasive fungal infections: a critical review. Clin Pharmacokinet. 2015:1\u201313. doi: 10.1007\/s40262-015-0297-8 .","DOI":"10.1007\/s40262-015-0297-8"},{"issue":"3","key":"399_CR31","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/clpt.2013.105","volume":"94","author":"SA Scott","year":"2013","unstructured":"Scott SA, Sangkuhl K, Stein CM, Hulot JS, Mega JL, Roden DM, et al. Clinical Pharmacogenetics implementation consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013;94(3):317\u201323. doi: 10.1038\/clpt.2013.105 .","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"399_CR32","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.2217\/pgs.09.72","volume":"10","author":"RE Janha","year":"2009","unstructured":"Janha RE, Sisay-Joof F, Hamid-Adiamoh M, Worwui A, Chapman HL, Opara H, et al. Effects of genetic variation at the CYP2C19\/CYP2C9 locus on pharmacokinetics of chlorcycloguanil in adult Gambians. Pharmacogenomics. 2009;10(9):1423\u201331. doi: 10.2217\/pgs.09.72 .","journal-title":"Pharmacogenomics."},{"issue":"3","key":"399_CR33","first-page":"304","volume":"59","author":"E Skjelbo","year":"1996","unstructured":"Skjelbo E, Mutabingwa TK, Bygbjerg I, Nielsen KK, Gram LF, Br\u00f8sen K. Chloroguanide metabolism in relation to the efficacy in malaria prophylaxis and the S-mephenytoin oxidation in Tanzanians. Clin PharmTher. 1996;59(3):304\u201311.","journal-title":"Clin PharmTher."},{"issue":"4","key":"399_CR34","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1086\/314683","volume":"179","author":"A Kaneko","year":"1999","unstructured":"Kaneko A, Bergqvist Y, Takechi M, Kalkoa M, Kaneko O, Kobayakawa T, et al. Intrinsic efficacy of proguanil against falciparum and vivax malaria independent of the metabolite cycloguanil. J Inf Dis. 1999;179(4):974\u20139.","journal-title":"J Inf Dis."},{"issue":"4","key":"399_CR35","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S0035-9203(96)90531-3","volume":"90","author":"M Edstein","year":"1996","unstructured":"Edstein M, Yeo A, Kyle D, Looareesuwan S, Wilairatana P, Rieckmann K. Proguanil polymorphism does not affect the antimalarial activity of proguanil combined with atovaquone in vitro. Trans Roy Soc Trop Med Hyg. 1996;90(4):418\u201321.","journal-title":"Trans Roy Soc Trop Med Hyg."},{"issue":"10","key":"399_CR36","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/S0169-409X(02)00065-0","volume":"54","author":"C Xu","year":"2002","unstructured":"Xu C, Goodz S, Sellers EM, Tyndale RF. CYP2A6 genetic variation and potential consequences. Adv Drug Deliv Rev. 2002;54(10):1245\u201356. doi: 10.1016\/S0169-409X(02)00065-0 .","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"399_CR37","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/01.fpc.0000239974.69464.f2","volume":"17","author":"J Sistonen","year":"2007","unstructured":"Sistonen J, Sajantila A, Lao O, Corander J, Barbujani G, Fuselli S. CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogen Genomics. 2007;17(2):93\u2013101.","journal-title":"Pharmacogen Genomics."},{"issue":"1","key":"399_CR38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1475-2875-13-2","volume":"13","author":"SR Marcsisin","year":"2014","unstructured":"Marcsisin SR, Sousa JC, Reichard GA, Caridha D, Zeng Q, Roncal N, et al. Tafenoquine and NPC-1161B require CYP 2D metabolism for anti-malarial activity: implications for the 8-aminoquinoline class of anti-malarial compounds. Malaria J. 2014;13(1):1.","journal-title":"Malaria J."},{"issue":"1","key":"399_CR39","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/tpj.2015.37","volume":"16","author":"B Maganda","year":"2016","unstructured":"Maganda B, Minzi O, Ngaimisi E, Kamuhabwa A, Aklillu E. CYP2B6* 6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria-coinfected patients. Pharmacogenomics J. 2016;16(1):88\u201395.","journal-title":"Pharmacogenomics J."},{"issue":"2","key":"399_CR40","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1128\/aac.01700-12","volume":"57","author":"EM Staehli Hodel","year":"2013","unstructured":"Staehli Hodel EM, Csajka C, Ariey F, Guidi M, Kabanywanyi AM, Duong S, et al. Effect of single nucleotide polymorphisms in cytochrome P450 isoenzyme and N-acetyltransferase 2 genes on the metabolism of artemisinin-based combination therapies in malaria patients from Cambodia and Tanzania. Antimicrob Agents Chemother. 2013;57(2):950\u20138. doi: 10.1128\/aac.01700-12 .","journal-title":"Antimicrob Agents Chemother"},{"key":"399_CR41","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/189686a0","volume":"189","author":"A Adam","year":"1961","unstructured":"Adam A. Linkage between deficiency of glucose-6-phosphate dehydrogenase and colour-blindness. Nature. 1961;189:686.","journal-title":"Nature"},{"key":"399_CR42","volume-title":"Biochemistry","author":"JM Berg","year":"2002","unstructured":"Berg JM, Tymoczko JL, Stryer L. Biochemistry. New York: W. H. Freeman and Company; 2002."},{"issue":"4","key":"399_CR43","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/bjh.12665","volume":"164","author":"L Luzzatto","year":"2014","unstructured":"Luzzatto L, Seneca E. G6PD deficiency: a classic example of pharmacogenetics with on-going clinical implications. Br J Hematol. 2014;164(4):469\u201380. doi: 10.1111\/bjh.12665 .","journal-title":"Br J Hematol."},{"issue":"7","key":"399_CR44","first-page":"1277","volume":"72","author":"JE Frank","year":"2005","unstructured":"Frank JE. Diagnosis and management of G6PD deficiency. Am Fam Physician. 2005;72(7):1277\u201382.","journal-title":"Am Fam Physician"},{"issue":"9","key":"399_CR45","doi-asserted-by":"publisher","first-page":"713","DOI":"10.2165\/11536520-000000000-00000","volume":"33","author":"I Youngster","year":"2010","unstructured":"Youngster I, Arcavi L, Schechmaster R, Akayzen Y, Popliski H, Shimonov J, et al. Medications and glucose-6-phosphate dehydrogenase deficiency. Drug Saf. 2010;33(9):713\u201326. doi: 10.2165\/11536520-000000000-00000 .","journal-title":"Drug Saf"},{"issue":"5","key":"399_CR46","first-page":"733","volume":"57","author":"MS Greenberg","year":"1961","unstructured":"Greenberg MS, Wong H. Studies on the destruction of glutathione-unstable red blood cells. J Lab Clin Med. 1961;57(5):733\u201346.","journal-title":"J Lab Clin Med"},{"issue":"1","key":"399_CR47","first-page":"80","volume":"70","author":"JN George","year":"1967","unstructured":"George JN, Sears DA, McCurdy PR, Conrad ME. Primaquine sensitivity in Caucasians: hemolytic reactions induced by primaquine in G-6-PD deficient subjects. J Lab Clin Med. 1967;70(1):80\u201393.","journal-title":"J Lab Clin Med"},{"issue":"3","key":"399_CR48","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3347\/kjp.2006.44.3.221","volume":"44","author":"S Krudsood","year":"2006","unstructured":"Krudsood S, Wilairatana P, Tangpukdee N, Chalermrut K, Srivilairit S, Thanachartwet V, et al. Safety and tolerability of elubaquine (bulaquine, CDRI 80\/53) for treatment of Plasmodium vivax malaria in Thailand. Kor J Parasitol. 2006;44(3):221\u20138.","journal-title":"Kor J Parasitol."},{"issue":"12","key":"399_CR49","doi-asserted-by":"publisher","first-page":"e4031","DOI":"10.1371\/journal.pone.0004031","volume":"3","author":"CI Fanello","year":"2008","unstructured":"Fanello CI, Karema C, Avellino P, Bancone G, Uwimana A, Lee SJ, et al. High risk of severe anaemia after chlorproguanil-dapsone\u00a0+\u00a0artesunate antimalarial treatment in patients with G6PD (A\u2212) deficiency. PLoS One. 2008;3(12):e4031. doi: 10.1371\/journal.pone.0004031 .","journal-title":"PLoS One"},{"issue":"8","key":"399_CR50","doi-asserted-by":"publisher","first-page":"e6682","DOI":"10.1371\/journal.pone.0006682","volume":"4","author":"Z Premji","year":"2009","unstructured":"Premji Z, Umeh RE, Owusu-Agyei S, Esamai F, Ezedinachi EU, Oguche S, et al. Chlorproguanil\u2013dapsone\u2013artesunate versus artemether\u2013lumefantrine: a randomized, double-blind phase III trial in african children and adolescents with uncomplicated Plasmodium falciparum malaria. PLoS One. 2009;4(8):e6682. doi: 10.1371\/journal.pone.0006682 .","journal-title":"PLoS One"},{"issue":"9742","key":"399_CR51","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/s0140-6736(10)60396-0","volume":"376","author":"L Luzzatto","year":"2010","unstructured":"Luzzatto L. The rise and fall of the antimalarial Lapdap: a lesson in pharmacogenetics. Lancet. 2010;376(9742):739\u201341. doi: 10.1016\/s0140-6736(10)60396-0 .","journal-title":"Lancet"},{"issue":"4","key":"399_CR52","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/02724936.1990.11747454","volume":"10","author":"V Choudhry","year":"1989","unstructured":"Choudhry V, Ghafary A, Zaher M, Qureshi M, Fazel I, Ghani R. Drug-induced haemolysis and renal failure in children with glucose-6-phosphate dehydrogenase deficiency in Afghanistan. Ann Trop Paediatr. 1989;10(4):335\u20138.","journal-title":"Ann Trop Paediatr"},{"issue":"3","key":"399_CR53","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/ng.528","volume":"42","author":"J Mu","year":"2010","unstructured":"Mu J, Myers RA, Jiang H, Liu S, Ricklefs S, Waisberg M, et al. Plasmodium falciparum genome-wide scans for positive selection, recombination hot spots and resistance to antimalarial drugs. Nat Genet. 2010;42(3):268\u201371.","journal-title":"Nat Genet"},{"issue":"12","key":"399_CR54","doi-asserted-by":"crossref","first-page":"7687","DOI":"10.1074\/jbc.M806944200","volume":"284","author":"DK Raj","year":"2009","unstructured":"Raj DK, Mu J, Jiang H, Kabat J, Singh S, Sullivan M, et al. Disruption of a Plasmodium falciparum multidrug resistance-associated protein (PfMRP) alters its fitness and transport of antimalarial drugs and glutathione. J Biol Chem. 2009;284(12):7687\u201396.","journal-title":"J Biol Chem"},{"issue":"5","key":"399_CR55","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00294-008-0214-x","volume":"54","author":"K Hayton","year":"2008","unstructured":"Hayton K, Su X-Z. Drug resistance and genetic mapping in Plasmodium falciparum. Curr Genet. 2008;54(5):223\u201339.","journal-title":"Curr Genet"},{"issue":"1","key":"399_CR56","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.actatropica.2011.07.003","volume":"120","author":"P Phompradit","year":"2011","unstructured":"Phompradit P, Wisedpanichkij R, Muhamad P, Chaijaroenkul W, Na-Bangchang K. Molecular analysis of pfatp6 and pfmdr1 polymorphisms and their association with in vitro sensitivity in Plasmodium falciparum isolates from the Thai-Myanmar border. Acta Trop. 2011;120(1):130\u20135.","journal-title":"Acta Trop"},{"issue":"6","key":"399_CR57","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/0092-8674(89)90330-9","volume":"57","author":"SJ Foote","year":"1989","unstructured":"Foote SJ, Thompson JK, Cowman AF, Kemp DJ. Amplification of the multidrug resistance gene in some chloroquine-resistant isolates of P. falciparum. Cell. 1989;57(6):921\u201330.","journal-title":"Cell"},{"issue":"3","key":"399_CR58","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1128\/AAC.00875-06","volume":"51","author":"G Humphreys","year":"2007","unstructured":"Humphreys G, Merinopoulos I, Ahmed J, Whitty C, Mutabingwa T, Sutherland C, et al. Amodiaquine and artemether\u2013lumefantrine select distinct alleles of the Plasmodium falciparum mdr1 gene in Tanzanian children treated for uncomplicated malaria. Antimicrob Agents Chemother. 2007;51(3):991\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"399_CR59","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/FTD.0b013e31815e93c6","volume":"30","author":"PE Ferreira","year":"2008","unstructured":"Ferreira PE, Veiga MI, Cavaco I, Martins JP, Andersson B, Mushin S, et al. Polymorphism of antimalaria drug metabolizing, nuclear receptor, and drug transport genes among malaria patients in Zanzibar, East Africa. Ther Drug Monit. 2008;30(1):10\u20135.","journal-title":"Ther Drug Monit."},{"issue":"4","key":"399_CR60","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s00228-008-0573-8","volume":"65","author":"MI Veiga","year":"2009","unstructured":"Veiga MI, Asimus S, Ferreira PE, Martins JP, Cavaco I, Ribeiro V, et al. Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam. Eur J Clin Pharmacol. 2009;65(4):355\u201363.","journal-title":"Eur J Clin Pharmacol"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13318-016-0399-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-016-0399-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-016-0399-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T00:23:08Z","timestamp":1658362988000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13318-016-0399-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,9]]},"references-count":60,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["399"],"URL":"https:\/\/doi.org\/10.1007\/s13318-016-0399-1","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,9]]}}}